Synovir thalidomide: Began Phase II pilot study

Celgene Corp. (CELG), Warren, N.J. Product: Synovir thalidomide Indication: Cachexia (wasting) in advanced cancer Status: Began Phase II pilot study in the U.K. of 100 mg orally for eight weeks, wit...